Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cross-reactivity

Cross-reactivity

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effect of HCV eradication on critical flicker frequency in HIV/HCV coinfected patients with advanced cirrhosis.

Revista clinica espanola·2022

Same author

ARAMIS: From systematic errors of NGS long reads to accurate assemblies.

Briefings in bioinformatics·2021

Same author

Potentially inappropriate medications in older adults living with HIV.

HIV medicine·2020

Same author

Combining plasma-based biosources to predict treatment response in NSCLC patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2020

Same author

A single mutation in cyclodextrin glycosyltransferase from Paenibacillus barengoltzii changes cyclodextrin and maltooligosaccharides production.

Protein engineering, design & selection : PEDS·2019

Same author

Combining plasma-based biosources to predict treatment response in NSCLC patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2018

Search research articles

Related Experiment Video

Updated: Aug 24, 2025

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Published on: June 5, 2021

Neutralizing antibodies for SARS-CoV-2 infection.

¹Juan Berenguer, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Doctor Esquerdo 46, 28007 Madrid, Spain. jbb4@me.com.

Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia

|October 26, 2022

Summary

Monoclonal antibodies (mAbs) are safe and effective for preventing and treating COVID-19, particularly in high-risk individuals. Further research is needed for specific groups and against new variants like Omicron.

More Related Videos

Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter

Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter

Published on: August 12, 2021

Author Spotlight: Studying Host-Virus Interactions with Pseudotyped Viruses

Author Spotlight: Studying Host-Virus Interactions with Pseudotyped Viruses

Published on: November 21, 2023

Related Experiment Videos

Last Updated: Aug 24, 2025

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Published on: June 5, 2021

Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter

Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter

Published on: August 12, 2021

Author Spotlight: Studying Host-Virus Interactions with Pseudotyped Viruses

Author Spotlight: Studying Host-Virus Interactions with Pseudotyped Viruses

Published on: November 21, 2023

Area of Science:

Immunology
Virology
Pharmacology

Background:

The COVID-19 pandemic spurred rapid development of monoclonal antibodies (mAbs) against SARS-CoV-2.
Existing clinical data primarily involves unvaccinated populations and predates the Omicron variant.

Purpose of the Study:

To evaluate the efficacy and safety of monoclonal antibodies (mAbs) for COVID-19 treatment and prevention.
To identify limitations in current research and suggest future directions.

Main Methods:

Review of clinical trial data on monoclonal antibody efficacy.
Analysis of safety and effectiveness in preventing severe COVID-19 outcomes.

Main Results:

Monoclonal antibodies (mAbs) demonstrated safety and effectiveness in preventing hospitalization and death in mild to moderate COVID-19 cases.
mAbs were also effective in treating severe disease in seronegative patients and for COVID-19 prevention.

Conclusions:

Monoclonal antibodies (mAbs) represent a valuable therapeutic option for COVID-19.
Future research must investigate mAb effectiveness in diverse populations (e.g., immunosuppressed, previously infected) and against emerging SARS-CoV-2 variants.